Verastem, Inc. (LON:0LOV)
9.52
-0.07 (-0.74%)
At close: Sep 12, 2025
Verastem Revenue
Verastem had revenue of $2.14M USD in the quarter ending June 30, 2025, a decrease of -78.63%. This brings the company's revenue in the last twelve months to $2.14M, down -78.63% year-over-year. In the year 2024, Verastem had annual revenue of $10.00M.
Revenue (ttm)
$2.14M
Revenue Growth
-78.63%
P/S Ratio
277.69
Revenue / Employee
$27.40K
Employees
78
Market Cap
433.14M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.00M | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 2.60M | 543.00K | 26.45% |
Dec 31, 2021 | 2.05M | -86.46M | -97.68% |
Dec 31, 2020 | 88.52M | 71.06M | 407.08% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Verastem News
- 4 weeks ago - Balyasny Asset Management L.P. Increases Stake in Verastem Inc - GuruFocus
- 5 weeks ago - Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer - Business Wire
- 5 weeks ago - Verastem, Inc. 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 5 weeks ago - Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Verastem climbs on Q2 beat as new ovarian cancer drug boosts topline - Seeking Alpha
- 6 weeks ago - Verastem Non-GAAP EPS of -$0.63 beats by $0.11, revenue of $2.14M beats by $1.02M - Seeking Alpha
- 6 weeks ago - Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - Business Wire
- 7 weeks ago - Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 - Business Wire